

Structural Characterization of Myotoxic Ecarpholin S From *Echis carinatus* Venom

Xingding Zhou,* Tien-Chye Tan,* S. Valiyaveetil,[†] Mei Lin Go,[‡] R. Manjunatha Kini,* Adrian Velazquez-Campoy,[§] and J. Sivaraman*

*Department of Biological Sciences, [†]Department of Chemistry, and [‡]Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore 117543, Singapore; and [§]Institute of Biocomputation and Physics of Complex Systems, Fundacion Aragon I + D, University of Zaragoza, Zaragoza 50009, Spain

ABSTRACT Phospholipase A₂ (PLA₂), a common toxic component of snake venom, has been implicated in various pharmacological effects. Ecarpholin S, isolated from the venom of the snake *Echis carinatus sochureki*, is a phospholipase A₂ (PLA₂) belonging to the Ser⁴⁹-PLA₂ subgroup. It has been characterized as having low enzymatic but potent myotoxic activities. The crystal structures of native ecarpholin S and its complexes with lauric acid, and its inhibitor suramin, were elucidated. This is the first report of the structure of a member of the Ser⁴⁹-PLA₂ subgroup. We also examined interactions of ecarpholin S with phosphatidylglycerol and lauric acid, using surface plasmon resonance, and of suramin with isothermal titration calorimetry. Most Ca²⁺-dependent PLA₂ enzymes have Asp in position 49, which plays a crucial role in Ca²⁺ binding. The three-dimensional structure of ecarpholin S reveals a unique conformation of the Ca²⁺-binding loop that is not favorable for Ca²⁺ coordination. Furthermore, the endogenously bound fatty acid (lauric acid) in the hydrophobic channel may also interrupt the catalytic cycle. These two observations may account for the low enzymatic activity of ecarpholin S, despite full retention of the catalytic machinery. These observations may also be applicable to other non-Asp⁴⁹-PLA₂ enzymes. The interaction of suramin in its complex with ecarpholin S is quite different from that reported for the Lys⁴⁹-PLA₂/suramin complex, where the interfacial recognition face (i-face), C-terminal region, and N-terminal region of ecarpholin S play important roles. This study provides significant structural and functional insights into the myotoxic activity of ecarpholin S and, in general, of non-Asp⁴⁹-PLA₂ enzymes.

INTRODUCTION

Phospholipase A₂ (PLA₂, enzyme classification number 3.1.1.4) enzymes constitute a large family of hydrolases that catalyze the hydrolysis of the *sn*-2 ester bond of phospholipids, producing free fatty acids and lysophospholipids (1–5). The PLA₂ superfamily was classified into 11 groups (6). The PLA₂ enzymes of groups I and II are major components of snake venom in the Elapidae and Viperidae families, respectively. Both groups exhibit Ca²⁺-dependent enzymatic activity, with Ca²⁺ binding to a Ca²⁺-binding loop and Asp⁴⁹ (according to the numbering system of Renetseder et al. (7)). Although a majority of group II PLA₂ enzymes have Asp at their position 49, this residue can occasionally be substituted with nonacidic residues such as Lys, Ser, Asn, and Arg (8–10). As expected, Asp⁴⁹-PLA₂ enzymes show high catalytic activity, whereas non-Asp⁴⁹-PLA₂ enzymes show low or no enzymatic activity. Interestingly, these non-Asp⁴⁹-PLA₂ enzymes exhibit strong myotoxic activity. Extensive research has been devoted to understanding the structure and function of Lys⁴⁹-PLA₂ enzymes. In Lys⁴⁹-PLA₂ enzymes, the Nε atom of Lys⁴⁹ occupies the space of the essential Ca²⁺ ion in Asp⁴⁹-PLA₂ enzymes, resulting in a substantial loss of catalysis (11,12). Furthermore, some studies suggest that a fatty-acid molecule may lie in the hydrophobic channel, leading to the interruption

of catalytic cycles (13,14). The myotoxic/cytolytic site of Lys⁴⁹-PLA₂ enzymes was identified using synthetic peptides (15–17). Subsequent studies using inhibition by heparin, chemical modification, and site-directed mutagenesis strongly supported the role of the C-terminal region in myotoxic activity, as reviewed in detail elsewhere (18). The positively charged patch on the surface of Lys⁴⁹-PLA₂ was suggested to play an active role in myotoxic activity (19,20). Ambrosio et al. (21) proposed that electrostatic interactions involving the C-terminal lysine residues play a role in the insertion of the hydrophobic “knuckle” induced by Lys¹²² into the membrane.

So far, most of the structural and functional studies of non-Asp⁴⁹-PLA₂ enzymes focused on Lys⁴⁹-PLA₂ enzymes. On the other hand, little is known about Ser⁴⁹-PLA₂ and other non-Asp⁴⁹-PLA₂ enzymes. Here we report on the enzymatic activity and myotoxic activity of a Ser⁴⁹-PLA₂ (ecarpholin S) from the venom of the snake *Echis carinatus sochureki*. We also determined crystal structures of ecarpholin S in its native form and in complexes with lauric acid, and of its myotoxic inhibitor, suramin. This is the first representative structure of the Ser⁴⁹-PLA₂ subgroup. Moreover, the mechanism of action of Ser⁴⁹-PLA₂ is elucidated, using structural data combined with biochemical and biophysical studies.

EXPERIMENTAL PROCEDURES

Materials

Ecarpholin S (belonging to the Ser⁴⁹-PLA₂ subgroup) was isolated from *Echis carinatus sochureki* snake venom (Latoxan, Rosans, France) by fol-

Submitted July 18, 2007, and accepted for publication May 22, 2008.

Address reprint requests to J. Sivaraman, Dept. of Chemistry, Faculty of Science, National University of Singapore, Singapore 117543, Singapore. E-mail: dbsjayar@nus.edu.sg.

Editor: Kathleen B. Hall.

© 2008 by the Biophysical Society
0006-3495/08/10/3366/15 \$2.00

doi: 10.1529/biophysj.107.117747

lowing the protocol of Polgar et al. (22), with minor modifications. Lyophilized venom was dissolved at 100 mg/mL in 50 mM Tris-HCl buffer, pH 7.0. Soluble components were loaded onto a Superdex 200 gel-filtration column (1.0 × 60 cm, Amersham Biosciences, Uppsala, Sweden) eluted with the same buffer. The sixth peak, estimated to have a molecular mass of ~14 kDa, was loaded onto an SP Sepharose High Performance cation-exchange column (5 mL, Amersham Biosciences). Ecarpholin S was eluted as a main peak from this column. We isolated ScPLA₂ (belonging to the Asp⁴⁹-PLA₂ subgroup) from *E. c. sochureki* venom according to the protocol of Jasti et al. (23). Both isolated proteins were confirmed by mass spectrometry and N-terminal sequencing. Suramin (8,8'-[carbonylbis[imino-3,1-phenylene]carbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium), phosphatidylglycerol (from egg yolk), and lauric acid were obtained from Sigma Chemical Co. (St. Louis, MO). All other reagents were of analytical grade.

Phospholipase enzymatic activity

The enzymatic activity of PLA₂ was measured by routine colorimetric assay, using a 1,2-dithio analog of diheptanoylphosphatidylcholine as substrate (PLA₂ assay kit, Cayman Chemicals, Ann Arbor, MI). The ScPLA₂ from *E. c. sochureki* served as positive control.

Myotoxic activity

Myotoxic activity is the damage to skeletal muscle leading to the release of cellular contents and the death of muscle cells. A number of snake venom proteins were shown to induce myotoxicity (18). Groups of five Swiss albino mice (18–22 g body weight) were injected (intramuscularly to the right gastrocnemius muscle) with 50, 75, or 100 µg of ecarpholin S in 50 µL of phosphate-buffered saline (PBS). After 3 h, the mice were anesthetized, and their blood was collected via heart puncture. The creatine kinase (CK) activity of serum was then measured using a kit (No. 2910) from Stanbio Laboratory (Boerne, Texas). One unit was defined as the amount of enzyme that produces 1 mmol of NADPH/min, and activity was expressed in units/liter. In inhibition studies, different doses of suramin were incubated with ecarpholin S (100 µg/mouse) for 15 min at 37°C before administration to animals.

Edema-inducing activity

The accumulation of fluid in the interstitial space and swelling during the inflammatory response are measured as edema. The PLA₂ from snake venom is a potent mediator of edema (5,24). The edema-inducing effects of ecarpholin S were measured in mice, as described earlier (25). Different doses of ecarpholin S were dissolved in 20 µL of PBS (pH 7.5) and administered via subplantar injection into the left footpad of Swiss albino mice under anesthesia. After 1 h, while still under anesthesia, mice were sacrificed by inhalation of carbon dioxide. Both their feet (injected and uninjected) were severed just above the plantar joint, and weighed. The percentage of edema was calculated from the difference in weight between injected and uninjected feet, with PBS as the control.

Isothermal titration calorimetry (ITC)

Ecarpholin S titrations with suramin were performed on a VP-ITC calorimeter system (MicroCal LLC, Northampton, MA) at 30°C. Solutions of 0.03 mM of ecarpholin S in 50 mM Tris-HCl (pH 7.4) were titrated with 0.5 mM suramin dissolved in the same buffer. The reaction cell contained 1.5 mL of the protein solution in buffer. Suramin was added in 5-µL increments at 500-s intervals. Injections of suramin solution in the same buffer, but in the absence of protein, were used to account for the heats of mixing and dilution. Binding parameters were estimated from isotherms obtained using scripts (Origin 7.0, OriginLab, Northampton, Massachusetts) developed in our laboratory.

Surface plasmon resonance

Surface plasmon resonance (SPR) studies were performed with Biacore 3000 (Biacore AB, Uppsala, Sweden). We prepared phosphatidylglycerol (PG)

liposomes by sonication, as previously described (26). Briefly, an appropriate amount of PG (2 mg) was dissolved in 2 mL of a chloroform solution, and the organic solvent was subsequently removed by vacuum desiccation. The resultant dried lipid film was rehydrated with PBS (pH 7.4) at the appropriate concentration at 25°C for 2 h. The resulting aqueous lipid mixture was sonicated until the solution appeared optically transparent in white light. A homogeneous liposomal suspension of approximately uniformly sized unilamellar vesicles with an average diameter (from dynamic light-scattering measurement) of 45 ± 7 nm was obtained. We performed immobilization of the PG liposome on the L1 chip, as described by the manufacturer. Briefly, PBS (pH 6.8) was used as the running buffer, the washing solution was 40 mM *N*-octyl β-D-glucopyranoside, and the regenerating solution was 10 mM NaOH. Experiments were performed at 25°C. Phosphatidylglycerol unilamellar vesicles (100 µL, 1 mM) were applied to the chip surface at a low flow rate (2 µL/min). To remove any multilamellar structures from the lipid surface, we injected NaOH (50 µL, 10 mM) at a flow rate of 50 µL/min, which resulted in a stable baseline corresponding to the lipid bilayer linked to the chip surface. The negative-control bovine serum albumin was injected (50 µL, 0.1 mg/µL in PBS) to confirm complete coverage of nonspecific binding sites. Ecarpholin S was diluted into a suitable final concentration, using the running buffer. All sensorgrams were processed by using automatic correction for nonspecific bulk refractive index effects. The equilibrium constant (K_D) was determined by the 1:1 Langmuir binding fitting model provided by the Biacore 3000 instrument software.

To study the interaction between ecarpholin S and lauric acid, ecarpholin S was immobilized on the sensor chip CM5 (Biacore AB) by the standard primary amine-coupling reaction. The equilibration of baseline was completed by the continuous flow of HBS-EP running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20, pH 7.4) through the chip. One of the four serial flow cells was activated for 10 min by injecting a 1:1 fresh mixture of 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 50 mM *N*-hydroxysuccinimide (NHS) at 25°C. Ecarpholin S was diluted with 10 mM HEPES buffer (pH 7.5) at a concentration of 50 µg/mL, and immobilized to the surface of sensor chip CM5. Finally, unreacted groups were blocked by injecting 1 M ethanolamine-HCl at pH 8.5 for 7 min, resulting in immobilized densities of 3500 RU. After stabilizing the baseline, Biacore data were collected at 25°C at a constant flow of 20 µL/min. Lauric acid was diluted into a suitable final concentration, using the running buffer. We used 70% ethanol as regeneration buffer. The equilibrium constant (K_D) was determined by the 1:1 Langmuir binding fitting model.

Crystallization and data collection

Ecarpholin S was crystallized by hanging-drop vapor-diffusion method using screens from Hampton Research (Aliso Viejo, CA). All crystallization experiments were performed at room temperature, with drops containing equal volumes (1 µL) of reservoir and protein solution. The protein was kept in a buffer of 50 mM Tris-HCl, pH 7.4, at a concentration of 10 mg/mL. The apo ecarpholin S crystal belonged to the space group P2₁2₁2₁ and was grown from a condition of 20% w/v polyethylene glycol (PEG) 3350, 20% v/v isopropanol, and 0.1 M sodium citrate, pH 5.6. Crystals of natural ecarpholin S/fatty-acid complex were crystallized in the presence of 2 M ammonium sulfate, 0.1 M Tris-HCl, pH 8.5, and belonged to the space group P3₁21. Ecarpholin S/suramin complex crystals were obtained using 10% w/v PEG3350, 10% v/v iso-propanol, and 0.1 M sodium citrate, pH 5.6, with a molar ratio of suramin/protein at 3:2. These crystals belonged to the space group P2₁. Before the collection of x-ray diffraction data, crystals were soaked in increasing steps of glycerol concentration (5% increase in each step; 30 min per step), and the final glycerol concentration was ~20% before flash-freezing using liquid N₂. The x-ray diffraction data for the apo and suramin complex were collected using an R-axis IV²⁺ image plate detector mounted on a RU-H3RHB rotating anode generator (Rigaku Corp., Tokyo, Japan). The data for the fatty-acid complex were collected at the X29 beamline (National Synchrotron Light Source (NSLS), Brookhaven National Laboratory, New York), using a Q315 CCD detector (Area Detector Systems Corp., Poway, CA). All data sets were processed using the HKL2000 suite (27). Crystallographic statistics are shown in Table 1.

TABLE 1 X-ray data collection and refinement statistics

| | Apo-ecarpholin S | Ecarpholin S-lauric acid complex | Ecarpholin S-suramin complex |
|--|---|----------------------------------|---|
| Data collection | | | |
| Cell parameters (Å) | a = 34.23, b = 39.48, c = 68.94 | a = b = 62.09, c = 124.25 | a = 51.45, b = 132.25, c = 86.10; β = 99.32 |
| Space group | P2 ₁ 2 ₁ 2 ₁ | P3 ₁ 21 | P2 ₁ |
| Molecules/asymmetry unit | 1 | 2 | 8 |
| Resolution range (Å) | 50–2.0 | 50–1.95 | 50–2.2 |
| Wavelength (Å) | 1.5418 | 0.97 | 1.5418 |
| Observed reflections | 32,276 | 214,445 | 186,658 |
| Unique reflections | 6,463 | 20,851 | 55,923 |
| Completeness (%) | 95.7 (87.4) | 99.7 (100) | 97.5 (86.6) |
| R_{sym} (%) [*] | 0.051 | 0.050 | 0.089 |
| $I/\sigma(I)$ | 24.7 (9.1) | 21.5 (2.4) | 10.8 (2.3) |
| Refinement and quality | | | |
| Resolution range (Å) | 20–2.0 | 30–1.95 | 30–2.3 |
| R_{work} (%) [†] | 19.2 | 22.8 | 21.7 |
| R_{free} (%) [‡] | 25.5 | 26.8 | 27.5 |
| rmsd bond lengths (Å) | 0.005 | 0.006 | 0.013 |
| rmsd bond angles(deg) | 1.3 | 1.3 | 1.6 |
| Average B-factors (Å ²) [§] | 30.5 | 29.1 | 33.7 |
| Main-chain | 28.4 | 26.3 | 31.9 |
| Side-chains | 31.3 | 30.0 | 33.2 |
| Waters | 38.0 | 35.4 | 32.0 |
| Lauric acid | | 50.2 | |
| Suramin chains | | | 36.4 |
| Ramachandran plot (%) | | | |
| Most favored regions | 90.4 | 89.4 | 85.9 |
| Additional allowed regions | 9.6 | 10.6 | 13.9 |
| Generously allowed regions | 0 | 0 | 0.1 |
| Disallowed regions | 0 | 0 | 0 |
| Number of protein atoms | 959 | 1918 | 7672 |
| Number of ligand atoms | 0 | 28 | 1031 |
| Number of waters | 96 | 243 | 370 |
| Protein Data Bank code | 2QHE | 2QHD | 3BJW |

^{*} $R_{\text{sym}} = \sum |I_i - \langle I \rangle| / \sum |I_i|$, where I_i is the intensity of the i th measurement, and $\langle I \rangle$ is the mean intensity for that reflection.

[†] $R_{\text{work}} = \sum |F_{\text{obs}} - F_{\text{calc}}| / \sum |F_{\text{obs}}|$, where F_{calc} and F_{obs} are the calculated and observed structure factor amplitudes, respectively.

[‡] $R_{\text{free}} = R_{\text{work}}$, but for 10% of the total reflections randomly selected and omitted from refinement.

[§]Individual B-factor refinement was performed.

Structural determination and refinement

Initial phases for apo ecarpholin S were obtained by the molecular replacement method with Molrep (28), using the Asp⁴⁹-PLA₂ structure from *Agkistrodon halys Pallas* as a search model (Protein Data Bank code 1JIA; sequence identity, ~56%). The initial R_{work} was 52%, and subsequent auto-model building was performed with ARP/wARP (29). The resultant model with the electron-density map was examined, and the model was built with the O program (30). Structures of the lauric acid and suramin complexes were determined using the apo ecarpholin S structure as the initial search model for the molecular replacement method, using the program Molrep (28). Omit maps were calculated for positioning the ligand. All three model-buildings and refinements were performed using O (30) and CNS (31) programs, with appropriate entries in their respective dictionaries. The overall geometry of the final models was analyzed by PROCHECK (32). Refinement statistics are given in Table 1.

RESULTS

Characterization of ecarpholin S

Ammodytin L, the first known Ser⁴⁹-PLA₂ isolated from the snake venom of *Vipera ammodytes*, was initially reported to

exhibit low enzyme activity (33). However, this activity was later attributed to contamination with ammodytotoxins (34). Polgar et al. (22) reported that Ser⁴⁹-PLA₂ ecarpholin S had 1.5–2.9 times more enzymatic activity than the recombinant human group II PLA₂. Our study shows that ecarpholin S has enzymatic activity (0.1 $\mu\text{mol}/\text{min}/\text{mg}$). However, compared with the activity of scPLA₂, an Asp⁴⁹-PLA₂ from the same venom, ecarpholin S shows only 0.5% activity (24.5 $\mu\text{mol}/\text{min}/\text{mg}$; see Fig. S1 in Supplementary Material, [Data S1](#)). Thus it is tempting to conclude that the activity of ecarpholin S is similar to that of some Lys⁴⁹-PLA₂ enzymes, which have low catalytic ability (35–41).

Ecarpholin S is a basic PLA₂ (calculated pI = 8.4), with several conserved, positively charged residues (particularly lysine) that are thought to be important in the myotoxicity of low molecular mass PLA₂ enzymes. Hence ecarpholin S was predicted to have myotoxic activity (22,42). Our results confirmed that ecarpholin S does exhibit myotoxic activity. Intramuscular injections of ecarpholin S increased serum

creatine kinase (CK) levels in a dose-dependent manner (Fig. 1). The injection of ecarpholin S at a dose of 100 $\mu\text{g}/\text{mouse}$ induced a significant increase in serum CK activity from 160 (± 40) units/L (mean \pm SD, $n = 5$) to 1900 (± 400) units/L ($n = 5$), compared with physiological saline solution (PBS, pH 7.3). Injecting ecarpholin S into the footpad of mice induced mild edema. At 20 $\mu\text{g}/\text{mouse}$, ecarpholin S induced $\sim 20\%$ edema compared with PBS-injected control mice (Fig. S2 in [Data S1](#)).

Structure of apo ecarpholin S

Although structures of a number of Asp⁴⁹ and Lys⁴⁹ PLA₂ enzymes are known, to date, no structure has been available for Ser⁴⁹ PLA₂ enzymes. Therefore, we determined the structure of ecarpholin S. The structure of its apo-form was solved by the molecular replacement method, using the Asp⁴⁹-PLA₂ structure from *Agkistrodon halys Pallas* as a starting model, and refined to an R_{work} of 19.2% ($R_{\text{free}} = 25.4\%$) up to 2.0-Å resolution. The model was refined with good stereochemical parameters (Table 1). Statistics for the Ramachandran plot from an analysis using PROCHECK (32) gave 90.4% of nonglycine residues in the most favored region, and no residues in the disallowed region.

The overall structure of ecarpholin S resembles that of classic group II PLA₂ enzymes. The superimposition of ecarpholin S with a classic group II PLA₂ (ScPLA₂; Protein Data Bank code 1OZ6) gave a root mean-square deviation (rmsd) of 1.2 Å for 120 C α atoms. Thus we will provide only a general overview of the structure and the subtle differences between ecarpholin S and other PLA₂ enzymes. Ecarpholin S consists of an N-terminal α -helix ($\alpha 1$), a loop equivalent to the Ca²⁺-binding loop, two long antiparallel α -helices ($\alpha 2$ and $\alpha 3$), the short two-stranded antiparallel β -sheet (β -wing), and the C-terminal loop region. The sequence of ecarpholin S

contains 14 cysteine residues, forming seven disulfide bonds. The pattern of disulfide bridges is identical to that of classic group II PLA₂ (5). Other main structural features include highly conserved catalytic residues (His⁴⁸, Tyr⁵², and Asp⁹⁹) and a hydrophobic channel (formed by residues such as Val², Leu⁵, Ile⁹, Pro¹⁸, Tyr²², and Gly³⁰).

The Ca²⁺-binding loop in Asp⁴⁹-PLA₂ is highly conserved (Tyr²⁸, Gly³⁰, Gly³², and Asp⁴⁹; Fig. 2). In Lys⁴⁹-PLA₂, the N ϵ of Lys⁴⁹ was shown to occupy the position of catalytically essential calcium, and thus reduces catalytic activity (12). In ecarpholin S, Asp⁴⁹ is replaced by Ser, and Tyr²⁸ in the Ca²⁺-binding loop is replaced by Phe. Although ecarpholin S partially retains its enzymatic activity, this activity is significantly lower than that of Asp⁴⁹-PLA₂. Fig. 3 shows the superimposition of the Ca²⁺-binding loop of ecarpholin S with scPLA₂, an Asp⁴⁹-PLA₂ from the same venom, and myotoxin II, a Lys⁴⁹-PLA₂ from *Bothrops asper* venom. The ScPLA₂ is a classic Asp⁴⁹-PLA₂, with Ca²⁺-binding at the highly conserved Ca²⁺-binding loop. In the case of myotoxin II, the long side-chain of Lys⁴⁹ extends into the Ca²⁺-binding loop and destabilizes Ca²⁺-binding. The previous homology modeling studies of ecarpholin S suggested that serine is a potential candidate for replacing Asp⁴⁹ without significantly affecting the Ca²⁺-binding capacity (22). But this model failed to predict the unique conformation of the Ca²⁺-binding loop (see below). However, in the ecarpholin S structure (Fig. 3), no calcium ion was found in the putative Ca²⁺-binding loop. A stretch of three residues (Gly³⁰-Trp³¹-Gly³²) of ScPLA₂ essentially bends to form a coordination bond with Ca²⁺. In the case of ecarpholin S, these three residues (Gly³⁰-Gly³¹-Gly³²) are linearly extended, and cause the carbonyl O of Gly³² to be moved away (~ 5 Å) from the putative Ca²⁺-binding position. In addition, the whole loop moves closer to the Ser⁴⁹ residue, and the N α of Gly³¹ nearly occupies the putative Ca²⁺-binding position (1.1 Å away from the Gly³¹ N). The position of O γ of Ser⁴⁹ of ecarpholin S does not occupy the position of O δ of Asp⁴⁹ of Asp⁴⁹-PLA₂ enzymes. The side-chain of the Ser⁴⁹ residue of ecarpholin S is too short to extend into the Ca²⁺-binding site (O γ of Ser⁴⁹ is 3.8 Å away from the putative Ca²⁺-binding site), unlike the N ϵ of Lys⁴⁹ in Lys⁴⁹ PLA₂ (Fig. 3). Furthermore, no water molecule was observed near the putative Ca²⁺-binding site of ecarpholin S. The nearest water molecule is ~ 3 Å away from the Ca²⁺-binding site, and thus no alternative electron density can be modeled as Ca²⁺. These observations strongly suggest that the conformation of the Ca²⁺-binding loop in ecarpholin S is different from that of Asp⁴⁹-PLA₂ enzymes and Lys⁴⁹-PLA₂ enzymes (Fig. 3), and the putative Ca²⁺-binding loop in ecarpholin S is not favorably placed to coordinate the Ca²⁺ ion, which partially explains its lower enzymatic activity than that of Asp⁴⁹-PLA₂. An attempt to cocrystallize ecarpholin S with 100 mM calcium chloride did not result in the incorporation of calcium ions in the Ca²⁺-binding loop. Binding studies using ITC showed that Ca²⁺ did not bind to ecarpholin S (Fig. S3 in [Data S1](#)). No calcium




FIGURE 1 Effects of ecarpholin S on levels of creatine kinase (CK) in mouse serum. Various doses of ecarpholin S (0 μg of ecarpholin S represents 50 μL of PBS buffer), with or without suramin, were injected into gastrocnemius muscles of mice, 3 h before their blood was collected. Released CK in plasma was measured, and results are presented as average \pm SD ($n = 5$).




FIGURE 2 Sequence alignment for PLA₂ and chemical structure of suramin. (A) Sequence comparison of ecarpholin S and other PLA₂ enzymes from snake venom. Identical residues are in red, nonsimilar residues are in black, and conserved residues are in blue. (B) Chemical structure of suramin.

ion was found at the putative Ca²⁺-binding loops of lauric acid and suramin complexes of ecarpholin S (see below). Thus Ser⁴⁹ and the putative Ca²⁺-binding loop of ecarpholin S do not support the binding of Ca²⁺ ions.

It is important to note that Ward et al. (43) carried out a mutational study of Lys⁴⁹ back to Asp, using Lys⁴⁹-PLA₂ bothropstoxin I. This mutant was still catalytically inactive, demonstrating that the single Asp⁴⁹ replacement with lysine alone was not important for the lack of enzymatic activity of this protein. Other features may also be important. In the case of ecarpholin S, Ser⁴⁹ is not ideal in terms of coordinating with the calcium ion. Moreover, the whole Ca²⁺-binding loop moves closer to the Ser⁴⁹ residue, and the Gly³¹ N nearly occupies the putative Ca²⁺ binding position. In the case of the Asp⁴⁹-PLA₂ subgroup, such as ScPLA₂, the Tyr²⁸ side-chain O hydrogen bonded with the Gly³⁵ backbone nitrogen atom (Fig. S4 in Data S1). In ecarpholin S, Tyr²⁸ was replaced by Phe, and no hydrogen bond was observed between

Gly³⁵ and Phe²⁸. In the Asp⁴⁹-PLA₂ subgroup, Tyr²⁸ is highly conserved, and this hydrogen bond appears to play an important role in stabilizing the Ca²⁺-binding loop. In addition, Gly³³ is a highly conserved residue in Asp⁴⁹-PLA₂, with a few exceptions, such as Lys³³ in CRV-W6D⁴⁹ from *Callosellasma rhodostoma* (44), Asn³³ in textilotoxin subunit C, and Ser³³ in the D subunit of textilotoxin from *Pseudonaja textilis* (45). Interestingly, all of these exceptions show no enzyme activity. Thus Gly³³ could be another critical residue for PLA₂ enzyme activity, although it is not directly involved with the coordination bonding with Ca²⁺. In scPLA₂, Gly³⁰-Trp³¹-Gly³² bends into a loop to form coordination bonds with Ca²⁺, and Gly³³ moves closer to the Ca²⁺ binding site. Replacing Gly³³ with a residue with a side chain, such as Lys in the case of CRV-W6D⁴⁹ and Ser in textilotoxin, could abolish the movement of these residues toward the Ca²⁺ binding site because of steric clashes. In ecarpholin S, Glu³³ occupies the Gly³³ position. Thus we




FIGURE 3 Stereo diagram of superposition of Ca²⁺-binding loop of PLA₂ enzymes. ScPLA₂ (Protein Data Bank code, 1OZ6; blue), ecarpholin S (red), and myotoxin II (Protein Data Bank code, 1CLP; yellow) were superimposed. Conformational differences of three different Ca²⁺-binding loops are shown. Three residues Gly³⁰-Trp³¹-Gly³² of scPLA₂ bend to form a coordination bond with Ca²⁺, whereas three residues Gly³⁰-Gly³¹-Gly³² of ecarpholin S extend linearly, causing Gly³² carbonyl O to move away from possible Ca²⁺ area (~5 Å). The whole loop moves closer to Ser⁴⁹ residue, and Nα of Gly³¹ nearly occupies putative Ca²⁺-binding position (1.1 Å away from Gly³¹ N), whereas in myotoxin II, Nε of Lys⁴⁹ residue occupies Ca²⁺ position. The side-chain of Ser⁴⁹ residue of ecarpholin S is too short to extend into Ca²⁺-binding site (Oγ of Ser⁴⁹ is 3.8 Å away from putative Ca²⁺-binding site). Image was prepared using the program Pymol (59).

speculate that the point mutation of Ser⁴⁹Asp alone in ecarpholin S may not restore its enzyme activity.

All catalytic residues are conserved in ecarpholin S. Critical residues of the catalytic triad of ecarpholin S (His⁴⁸, Tyr⁵², and Asp⁹⁹) are anchored tightly to the scaffold composed of two α helices, and superimpose with corresponding residues of two structural homologues from Asp⁴⁹ and Lys⁴⁹-PLA₂ enzymes with nearly identical conformations (rmsd of 0.5 Å) (Fig. S4 in Data S1). The hydrophobic channel that provides access to the catalytic site is also highly conserved. Therefore, we propose that the nonideal conformation of the Ca²⁺-binding loop is responsible for the low enzyme activity of ecarpholin S.

The structure of ecarpholin S shows several positively charged patches on the surface of the molecule (Fig. S5 in Data S1) that may interact with negatively charged counterparts on the membrane, to initiate the process of interrupting the integrity of the cell. For example, a Lys⁴⁹-PLA₂ such as myotoxin I was shown to interrupt negatively charged liposomes in vitro (46). To understand these interactions further, we studied the binding between PG and ecarpholin S, using SPR (Fig. 4). Phosphatidylglycerol was immobilized to the surface of the L1 chip in the experiment, and ecarpholin S was the analyte. Sensorgrams show that PG

binds to ecarpholin S in a dose-dependent manner. The dissociation constant (K_D) calculated from these sensorgrams was 0.5 μ M.

Structure of ecarpholin S/lauric acid complex

Our crystallization experiments showed that ecarpholin S can be crystallized in different conditions. The structure of ecarpholin S in P3₁21 crystal form was determined at a 1.95-Å resolution ($R_{\text{work}} = 22.8\%$, and $R_{\text{free}} = 26.8\%$). The model was refined with good stereochemical parameters (Table 1). During structural refinement, the hydrophobic channel of ecarpholin S showed an extra electron density to accommodate ~ 12 atoms. Because the crystallization conditions did not contain polyethylene glycol, and considering the extra electron density location, size, and geometry, this electron density was modeled as lauric acid (Fig. 5 A), although no lauric acid was added during the experiments. However, no direct evidence is available to confirm the presence of lauric acid, and the assignment of the electron density to this molecule must be regarded with caution. We do not rule out the possibility of the binding of some other metabolite at this site. Moreover, in the presence of isopropanol (10–20%) in the crystallization conditions of the apo and suramin ecarpholin S complex (see below), no lauric acid was evident. Probably the naturally bound lauric acid was removed by the organic solvent present in the crystallization conditions, whereas the lauric-acid complex was crystallized with 2 M ammonium sulfate, and because of the high hydrophobic interactions, the lauric acid was retained in the hydrophobic channel of ecarpholin S.

The lauric acid was well-defined in the electron-density map (Fig. 5 A). No calcium ion was identified at the putative Ca²⁺-binding loop. The overall structure of ecarpholin S in the complex was similar to that of apo-ecarpholin S in P2₁2₁2₁ crystal form. The bound ligand undergoes hydrophobic interactions with several residues of the hydrophobic channel such as Val², Leu⁵, Gly⁶, Phe¹⁸, Cys⁴⁵, and Tyr⁵². The acidic head is stabilized by hydrogen-bonding contact with the N δ 1 atom of His⁴⁸, whereas the tail of the ligand extends into the hydrophobic channel. The presence of such a natural fatty-acid molecule was previously reported in the crystal structures of three different Lys⁴⁹-PLA₂ enzymes (13,14,21).

The superposition of the ecarpholin S/lauric acid complex on the known fatty-acid complexes indicates that all ligands are in the same region of PLA₂ enzymes (Fig. 6), whereas the conformation of the alkyl tail is different. The alkyl tail of lauric acid of the ecarpholin S complex is close to the i-face, whereas the tails of the other three fatty acids take different orientations, closer to the N-terminal region. These three fatty acids are longer, and are in generally extended conformations. The observed electron density from *Fo-Fc* maps and simulated annealing omit maps did not permit us to model our ligand with an extended conformation. The ecarpholin S-bound lauric acid could be the result of phospholipid hy-




FIGURE 4 Studies of binding of phosphatidylglycerol (PG) and lauric acid to ecarpholin S, using SPR. Concentration-dependent binding and real-time binding affinity measurement of phosphatidylglycerol (A) and lauric acid (B) to ecarpholin S used Biacore 3000. Analyte was injected for 3 min, and dissociation was monitored for more than 15 min. Reference and blank data are subtracted. (A) Analyte concentrations were 20 nM, 38 nM, 75 nM, 150 nM, and 300 nM. (B) Analyte concentrations were 10 μ M, 20 μ M, 30 μ M, 40 μ M, and 50 μ M.




FIGURE 5 $F_o - F_c$ map shows ligand in ecarpholin S structure. (A) $F_o - F_c$ map in hydrophobic channel of ecarpholin S. Bound lauric-acid molecules were omitted before refinement and map calculation. Map was contoured at a level of 2σ . (B) $F_o - F_c$ map for suramin complex. Inhibitor suramin molecules were omitted before refinement and map calculation. Map was contoured at a level of 2σ . All suramin molecules of asymmetric unit have the equivalent quality of electron density; one representative molecule is shown here. Images were prepared using the program Pymol (59).

drolisis by ecarpholin S, followed by a failure of product release. Alternatively, it could be a transient fatty acyl intermediate in the catalytic cycle that leads to the release of fatty acid in the next step.

The $F_o - F_c$ and omit maps of the apo and ecarpholin S/suramin complex (see below) were carefully examined for the presence of any PEG or fatty-acid molecules in the hydrophobic channel, because both conditions used for crystallization contained PEG3350. In these structures, no electron densities could be modeled as either a fatty acid or a PEG molecule. It is important to note that the crystals for both the apo-enzyme and the lauric acid complex were obtained from the same batch of protein; the only difference involved their crystallization conditions.

Watanabe et al. (47) obtained the MjTX-II/stearic acid complex from a cocrystallization experiment. In the hydrophobic channel of MjTX-II, a second stearic acid was observed in the vicinity of the first stearic acid, as shown in Fig. 6. In the case of the ecarpholin S/lauric acid complex, no electron density was observed to model the second fatty

acid or other polymeric molecules in the corresponding location. This result further suggests that lauric acid could be a natural ligand for ecarpholin S, specifically binding at one location of the hydrophobic channel. Thus, this complex appears to be different from the *in vitro* MjTX-II/stearic acid complex (47).

To understand these interactions further, we studied the interaction between lauric acid and ecarpholin S, using SPR (Fig. 4). Sensorgrams showed that lauric acid binds to ecarpholin S in a dose-dependent manner, exhibiting characteristic slow-binding and slow-dissociation curves. The dissociation constant (K_D) calculated from these sensorgrams was $4.2 \mu\text{M}$.

Structure of ecarpholin S/suramin complex

Suramin, a highly charged polysulfonated compound, inhibits the myonecrosis caused by some snake venoms and $\text{Lys}^{49}\text{-PLA}_2$ enzymes (20,48–50). Similarly, suramin significantly inhibits the myotoxic activity of ecarpholin S (Fig.




FIGURE 6 Superimposition of lauric acid in hydrophobic channel of ecarpholin S and three Lys⁴⁹-PLA₂ enzymes. Structure of MjTX-II/stearic acid (Protein Data Bank code, 1XXS, *red*), PrTX-II/fatty acid (Protein Data Bank code, 1QLL, *blue*), ACL/lauric acid (Protein Data Bank code, 1S8G, *yellow*), and ecarpholin S/lauric acid (*cyan*) complexes were superimposed. Lauric acid molecules are shown as lines. Image was prepared using the program Pymol (59).

1). To understand these interactions, we determined the crystal structure of the ecarpholin S/suramin complex. Data for this complex were collected at a 2.3-Å resolution, and the structure was solved and refined to an R_{work} of 21.7% ($R_{\text{free}} = 27.5\%$). The model was refined with good stereochemical parameters (Table 1). Suramin molecules were well-defined in the electron-density map (Fig. 5 *B*). No calcium ion was identified at the putative Ca²⁺-binding loop. The asymmetric unit consists of eight ecarpholin S monomers, with 12 suramin molecules (3:2 inhibitor/protein ratio). The eight monomers could be divided into four dimers, each sandwiching three suramin molecules (Fig. 7). The conformations of all eight monomers were nearly identical. The superimposition of apo ecarpholin S and the ecarpholin S/suramin complex gave an rmsd in the range of 0.9–1.0 Å for all chains. Similarly, the rmsd for the lauric-acid complex molecule A (or B) and suramin complex was in the range of 0.6–0.8 Å for each molecule. Thus, the complex formation with suramin did not result in any significant conformational changes in the protein.

In the ecarpholin S/suramin complex, the entrance of the hydrophobic channel of monomers A and B of the dimer are occupied by three suramin molecules through hydrogen-bonding and hydrophobic interactions. Most residues that form hydrogen bonds with suramin are located in the i-face (Fig. 8 *A*). Suramin also interacts with the C-terminal region of ecarpholin S. In addition, Asn¹¹⁴, Lys¹¹⁵, and Lys¹¹⁶ of monomer A form several hydrogen-bonding contacts with suramin (Fig. 8 *B*). Suramin forms interactions with the N-terminal helix of ecarpholin S (Fig. 8 *C*). Overall, the suramin-recognition sites of ecarpholin S are mainly from the i-face, C-terminal, and N-terminal regions through hydrogen-bonding and hydrophobic interactions. In contrast, in the Lys⁴⁹-PLA₂ Basp-II/suramin complex, suramin-recognition sites are located near the putative Ca²⁺-binding loop or on the side of the i-face (Arg³⁴, Lys⁵³, and Lys⁶⁹) (Figs. 7 and 8

D). In this case, suramin interacts with Basp-II, with a stoichiometric ratio of 1:1. Thus, in terms of the stoichiometric ratio and the interaction site, the ecarpholin S/suramin complex is different from that of the Basp-II/suramin complex.

To test whether this observed difference is attributable to the ratios between suramin and ecarpholin S, we crystallized the complex at various suramin/protein ratios. The crystal complex structure remained the same at the 3:2 ratios (inhibitor/protein). In all crystal structures obtained, suramin molecules were fully occupied in all positions in the asymmetric unit described above. We think that the surplus protein present in the solution did not affect the crystallization of the ecarpholin S/suramin complex.

In the crystal structure, the ecarpholin S/suramin complex forms dimers as the minimal unit, and four dimers (octamers) are found in the asymmetric unit. This is consistent with gel-filtration experiments. In the gel filtration, the ecarpholin S and suramin mixture eluted as a dimer (Fig. 9), whereas ecarpholin S alone eluted as a monomer. This shows that suramin functions as a linker molecule between the monomers, and induces the dimerization of ecarpholin S, as revealed by the crystal structure.

The interaction of suramin with ecarpholin S was further examined by preliminary ITC experiments. The binding isotherm and nonlinear least-squares analysis of the data are shown in Fig. 10. Fig. 10, *top* shows the heat effect associated with successive injections until saturation is reached. Fig. 10, *bottom* shows the integrated heat effects associated with each injection. In the analysis, the concentration of ecarpholin S was considered on the basis of monomers. The titration was nonmonotonic, exhibiting a biphasic shape that does not correspond with stoichiometries for independent binding sites. This biphasic shape is not considered an artifact, because it always appeared and can be accounted for with the binding model used in the analysis. Moreover, blank titrations that injected ligand into the buffer yielded constant heat effects.

Because the gel-filtration and x-ray diffraction results indicated that suramin promotes dimerization, and the stoichiometry is 3:1 (suramin/dimer), the simplest way to analyze titration is to consider a fully cooperative two-state model in which n ligand molecules bind to a dimer at once. Then, only two states are present: a free protein monomer, and a dimer with n bound ligands. The chemical equilibrium scheme for this model, as been outlined in the Appendix, is:



where the dimerization energetics are implicitly included in the binding energetics, and no intermediate states appear. Thus, the global-equilibrium constant will be a combination of the equilibrium constant for ligand binding, K_L , and the equilibrium constant for dimerization, K_d :




FIGURE 7 Stereo diagram of comparison of suramin bound to ecarpholin S and Basp-II. (A) Three suramin molecules are sandwiched between monomer A and monomer B of ecarpholin S. (B) In Basp-II/suramin complex (Protein Data Bank code, 1Y4L), only one suramin molecule is located between the two monomers. Image was prepared using the program Pymol (59).

$$K = K_L K_d, \quad (2)$$

and the global enthalpy will be a combination of the ligand-binding enthalpy, ΔH_L , and the dimerization enthalpy, ΔH_d :

$$\Delta H = \Delta H_L + \Delta H_d. \quad (3)$$

If it is assumed that an ecarpholin dimer binds three ligand molecules ($n = 3$), the nonlinear analysis yields the following values: $K = (2.1 \pm 0.6) \times 10^{20} (M^{-4})$, $\Delta H = -27 \pm 1$ kcal/mol, $N = 0.69 \pm 0.05$. The theoretical curve is able to reproduce the experimental curve reasonably well, including the initial part of the titration where the heat effect slightly increases. Because the parameter N corrects for the effective concentration of protein, there are two possible explanations for N not being equal to unity: (1), assuming that the suramin concentration is accurately determined, only 70% of the protein is binding-competent; or (2), less than three suramin molecules bind per dimer under the conditions and concentrations used in the ITC experiments.

If it is assumed that an ecarpholin dimer binds two ligand molecules ($n = 2$), the nonlinear analysis yields the following

values: $K = (1.9 \pm 0.3) \times 10^{14} (M^{-3})$, $\Delta H = -26.7 \pm 0.8$ kcal/mol, $N = 1.09 \pm 0.05$. Again, the theoretical curve is able to reproduce the experimental curve reasonably well, including the initial part of the titration where the heat effect slightly increases, and the fit is significantly better than the previous one with three ligand molecules bound per dimer.

The titration experiments cannot be analyzed with a model considering two or three independent binding sites (51), because the thermodynamic parameters obtained, and in particular the stoichiometry values, are not realistic (i.e., N values much lower than 1).

DISCUSSION

An explanation for the mechanism of lipid hydrolysis by Asp⁴⁹-PLA₂ enzymes was proposed by Verheij et al. (52), and was subsequently modified, based on the crystal structure of PLA₂ from *Naja atra* venom complexed with a transition-state analogue (53,54). In those models, the roles of active sites, the Ca²⁺-binding loop, the hydrophobic channel, and the i-face were established. A structural characterization of PLA₂ isoforms with low or no enzymatic activity will help us




FIGURE 8 Comparison of interaction region of suramin with ecarpholin S and Basp-II. (A) Suramin interacts with i-face region of ecarpholin S. (B) Suramin interacts with C-terminal region of ecarpholin S. (C) Suramin interacts with N-terminal region of ecarpholin S. (D) Suramin interacts with putative Ca^{2+} -binding loop region of Basp-II (Protein Data Bank code, 1Y4L). Hydrogen bonds are shown in green (dashed lines). Images were prepared using the program Pymol (59).

further understand the mechanism of catalysis. In a number of group II PLA_2 enzymes, one of the critical residues for Ca^{2+} -binding, Asp⁴⁹, is replaced by nonacidic residues. As expected, despite the conserved Ca^{2+} -binding loop, hydrophobic channel, and i-face, these isoforms have low or no activity. However, crystal structures of PLA_2 enzymes in which Asp⁴⁹ is replaced by nonacidic residues are not available, with the exception of Lys⁴⁹- PLA_2 . Hence, we investigated whether the low enzymatic activity of these PLA_2 enzymes could be explained by the same factors as with Lys⁴⁹- PLA_2 . As shown here, the conformation of the Ca^{2+} -binding loop of ecarpholin S, a Ser⁴⁹- PLA_2 , is quite different (Fig. 6). The Asp⁴⁹- PLA_2 enzymes have a canonical Ca^{2+} -binding loop, with Ca^{2+} in the binding pocket. In Lys⁴⁹-

PLA_2 enzymes, the N ϵ of the Lys⁴⁹ residue occupies the position of the Ca^{2+} ion, and displaces it. In ecarpholin S, the putative Ca^{2+} -binding loop is distorted, and its conformation is not suitable for calcium binding. This inability to bind Ca^{2+} is further supported by ITC experiments (Fig. S3 in Data S1). This new Ca^{2+} -binding loop conformation was not observed in any other PLA_2 structures.

Although Lys⁴⁹, Ser⁴⁹, and other non-Asp⁴⁹- PLA_2 enzymes show limited or no enzymatic activity, they exhibit strong myotoxic activities (including ecarpholin S). The mechanism of their action remains interesting, because it is believed to be independent of phospholipid hydrolysis activity. Many proposals were put forward to explain Lys⁴⁹- PLA_2 myotoxic activity, and they were summarized in re-




FIGURE 9 Gel-filtration studies on oligomerization of ecarpholin S induced by suramin. (A) Elution profiles of ecarpholin S without suramin. Column is Superdex 200 (Amersham Biosciences). (B) Elution profiles of ecarpholin S with suramin (ecarpholin S/suramin = 1:1, molar ratio). (C) Elution profiles of ecarpholin S with suramin. (ecarpholin S/suramin = 1:2, molar ratio). (D) Column calibrated with gel-filtration standard (1.35–670 kDa from Bio-Rad Laboratories, Hercules, California).

views (18,19). These myotoxins should have a specific “functional site” responsible for their potent myotoxic activities. Synthetic peptides (KKYRYYLKPLCKK and KKYKAYFKLKCKK) from the C-terminal region K115–K129 of *B. asper* myotoxin II and *A. p. piscivorus* Lys⁴⁹ PLA₂, respectively, induce cytolytic effects and play a critical role in myotoxicity (15–17,55). This region was also identified as a binding site for heparin (a myotoxin inhibitor) in rat class IIA secreted PLA₂ (51). Treatment with cyanogen bromide leads to cleavage of the N-terminal octapeptide of *B. asper* myotoxin II, resulting in a significant decrease in its membrane-damaging activities, such as liposome disruption and myotoxicity (56–58). Thus, the N-terminal region is also responsible for myotoxicity. The ecarpholin S/suramin complex shows that it simultaneously binds to the C-terminal, N-terminal, and i-face. These findings strongly suggest that one or more of these three regions could be functionally relevant regions in myotoxicity. The comparison of C-terminal residues Lys¹¹⁵–Gly¹²⁹ (KKYTYYPNFWCKG) of ecarpholin S with the corresponding segment of *B. asper* myotoxin II and *A. p. piscivorus* Lys⁴⁹–PLA₂ reveals that they possess combinations of positively charged and hydrophobic residues. In the ecarpholin S/suramin complex, suramin is mainly held together by a combination of both hydrogen-bonding and hydrophobic interactions with residues, such as Lys¹¹⁵, Lys¹¹⁶, Phe124, and Trp125. Because Lys¹¹⁵ and Lys¹¹⁶ are highly conserved among all three PLA₂ enzymes, they may play a more crucial role in the activity of myotoxic PLA₂ enzymes.

Furthermore, our SPR experiments suggest that negatively charged phospholipids, such as PG, interact with ecarpholin S. Based on our studies, we propose a hypothesis to explain the myotoxic activity of ecarpholin S: positively charged residues, located in the i-face of the protein, initiate binding with the anionic acceptor(s) (phospholipids) on the membrane, leading to a further strengthening of this interaction by hydrophobic and aromatic residues located at the entrance of the hydrophobic channel. The C-terminal (mainly Lys¹¹⁵ and Lys¹¹⁶) and N-terminal positive patches interact further with the membrane, perturbing the membrane’s integrity and inducing cell death. This hypothesis is highly consistent with evidence from noncrystallographic studies involving chemical modifications, synthetic peptides, inhibitors, and site-directed mutagenesis (15–17,55–58).

Our preliminary studies to characterize the thermodynamics of the ecarpholin/suramin interaction are in agreement with suramin promoting the dimerization of ecarpholin. The cooperative model, in which only two states are considered (free protein monomer and ligand-bound protein dimer), is able to describe qualitatively and quantitatively the calorimetric titrations reasonably well. According to our results, the ecarpholin dimer might bind two suramin molecules under the conditions and concentrations used for ITC experiments. Although three suramin molecules bound to an ecarpholin dimer are observed in the crystallographic structure, one of the three suramin molecules in every dimer has higher a B-factor, suggesting the possibility of partial occupancy. In addition, the protein and ligand concentrations are




FIGURE 10 Interaction between ecarpholin S and suramin, using ITC. Raw thermal power signal (*top*) and plot of integrated heat versus ligand/protein molar ratio (*bottom*). Conditions: 0.03 mM ecarpholin S titrated with 5- μ L injections of 0.5 mM suramin. Both protein and suramin solutions were in 50 mM Tris-HCl at pH 7.0 and 30°C. In the analysis, protein concentration was considered on a monomer basis (0.03 mM). Titration curve was analyzed using a fully cooperative model in which n ligand molecules ($n = 2, 3$) bind to a protein dimer. Thermodynamic binding parameters obtained are: $K = (2.1 \pm 0.6) \times 10^{20} (M^{-4})$, $\Delta H = -27 \pm 1$ kcal/mol, $N = 0.69 \pm 0.05$ for $n = 3$ (*dashed line*); and $K = (1.9 \pm 0.3) \times 10^{14} (M^{-3})$, $\Delta H = -26.7 \pm 0.8$ kcal/mol, $N = 1.09 \pm 0.05$ for $n = 2$ (*solid line*).

significantly higher in the crystallization setup. If two suramin molecules bind to a protein dimer, the global Gibbs energy is -19.8 kcal/mol, whereas if three suramin molecules bind to a protein dimer, the global Gibbs energy is -28.2 kcal/mol. This global Gibbs energy corresponds to the Gibbs energy for the binding of two or three ligand molecules plus the Gibbs energy for ecarpholin dimerization. The enthalpy values obtained from the analysis are observed values with a possible influence on the ionization enthalpy of the buffer. Additional experiments would be required to assess the extent of possible protonation events coupled to ligand

binding, and to estimate the buffer-independent binding enthalpies.

The fully cooperative two-state model for suramin binding can reproduce the shape of the experimental titrations, which supports the hypotheses that suramin promotes dimerization and the population of ligand-free dimers is not significant, as observed using gel-filtration chromatography. A more realistic model would include the ligand-free monomer-dimer equilibrium. A more detailed discussion about the adequate binding model would be appropriate in future work. The influence and explicit consideration of the protein monomer-dimer equilibrium, modulated by ligand binding, would require additional information from ultracentrifugation experiments or binding experiments at different concentrations of protein, or by performing reverse titrations in which the protein is injected into the ligand solution.

In conclusion, the structure of the first representative member of the Ser⁴⁹-PLA₂ subgroup of enzymes, ecarpholin S and its complexes with fatty acid and suramin, is quite different from the structures of Lys⁴⁹-PLA₂ and Asp⁴⁹-PLA₂ enzymes. First, the Ca²⁺-binding loop of ecarpholin S has a unique conformation which is not ideal for coordinating with Ca²⁺. Secondly, the ecarpholin S/suramin complex shows that, in addition to the i-face, suramin interacts with both the C-terminal and N-terminal regions of ecarpholin S. Such interactions were not observed in the previous report of the Lys⁴⁹-PLA₂/suramin complex (20). These findings broaden the understanding of the action of non-Asp⁴⁹-PLA₂ enzymes, and should be helpful in the development of new drugs for the treatment of myonecrosis.

APPENDIX

The procedure for the analysis of ITC experiments, according to the cooperative model (Eq. 1), is rather straightforward, starting from the conservation equations for protein and ligand:

$$\begin{aligned} [M]_T &= [M] + 2[M_2L_n] \\ [L]_T &= [L] + n[M_2L_n], \end{aligned} \quad (4)$$

where M and L represents the protein monomer and the ligand molecule, respectively. The global-equilibrium constant, K , governs the partition into bound and free species:

$$K = K_L K_d = \frac{[M_2L_n]}{[M]^2 [L]^n}, \quad (5)$$

where K_L is the equilibrium constant for ligand binding, and K_d is the dimerization constant for the protein. Therefore, Eq. 4 can be written in terms of free concentrations:

$$\begin{aligned} [M]_T &= [M] + 2K[M]^2[L]^n \\ [L]_T &= [L] + nK[M]^2[L]^n. \end{aligned} \quad (6)$$

The free concentration of protein, $[M]$, can be calculated by solving analytically the first equation of the previous set:

$$[M] = \frac{\sqrt{1 + 8K[M]_T[L]_T^n} - 1}{4K[L]_T^n}, \quad (7)$$

and it can be introduced into the second equation of the previous set, to calculate the free-ligand concentration, $[L]$:

$$[L]_T = [L] + \frac{n(\sqrt{1 + 8K[M]_T[L]_T^n} - 1)^2}{16K[L]_T^n}, \quad (8)$$

which can be solved numerically (e.g., by the Newton-Raphson method). Once the free-ligand and free-protein concentrations are known, the concentration of the complex can be calculated from Eq. 5:

$$[M_2L_n] = K[M]^2[L]^n. \quad (9)$$

The concentration of total ligand and total protein in the calorimetric cell after each injection i is calculated as:

$$[L]_{T,i} = [L]_0 \left(1 - \left(1 - \frac{v}{V} \right)^i \right) \\ [M]_{T,i} = [M]_0 \left(1 - \frac{v}{V} \right)^i, \quad (10)$$

where $[L]_0$ is the concentration of ligand in the syringe, $[M]_0$ is the initial concentration of protein in the cell, and v and V are the injection volume and the cell volume, respectively. The factor $(1 - v/V)$ is the dilution factor after each injection.

Given the total concentration of protein and ligand in the calorimetric cell before and after each injection (Eq. 10), and assuming a certain value for the equilibrium constant K , the concentration of free ligand and free protein, before and after each injection, can be calculated by solving Eqs. 7 and 8, and the concentration of the complex can be calculated from Eq. 9. Then the heat q_i associated with the injection i is calculated for the sequential ligand-binding model:

$$q_i = V\Delta H \left([M_2L_n]_i - [M_2L_n]_{i-1} \left(1 - \frac{v}{V} \right) \right) + q_d, \quad (11)$$

where ΔH is the global enthalpy (Eq. 3), and q_d is the so-called “dilution heat” (constant background heat effect due to unspecific phenomena such as ligand dilution upon injection and injection turbulence). Nonlinear least-square regression, using Eq. 11, will provide K and ΔH as adjustable parameters. It is customary to include an additional parameter N (i.e., using $N[M]_T$ instead of $[M]_T$ in all previous equations) to account for a different stoichiometry than the one expected or a mismatch between the measured concentrations and the actual ones.

SUPPLEMENTARY MATERIAL

To view all of the supplemental files associated with this article, visit www.biophysj.org.

Some of the x-ray data for this study were measured at beamline X12C of the National Synchrotron Light Source, Brookhaven National Laboratory. We acknowledge Dr. Anand Saxena for assistance during data collection. We also thank Mr. Shashikant Joshi from the Protein and Proteomic Centre of Department of Biological Sciences, National University of Singapore, for providing research facilities, and for useful discussions.

Financial support came principally from the Offices of Biological and Environmental Research and of Basic Energy Sciences of the United States Department of Energy, and from the National Center for Research Resources of the National Institutes of Health. A.V.C. acknowledges funding from the Spanish Ministry of Education and Science (grant SAF2004-07722 and Ramon y Cajal Research Contract), and from Fundacion Aragon I + D (Diputacion General de Aragon). This work was also supported by the

Academic Research Fund, Ministry of Education, Singapore (grant R-154-000-245-112).

REFERENCES

- Davidson, F. F., and E. A. Dennis. 1990. Evolutionary relationships and implications for the regulation of phospholipase A2 from snake venom to human secreted forms. *J. Mol. Evol.* 31:228–238.
- Dennis, E. A. 1994. Diversity of group types, regulation, and function of phospholipase A2. *J. Biol. Chem.* 269:13057–13060.
- Dennis, E. A. 1997. The growing phospholipase A2 superfamily of signal transduction enzymes. *Trends Biochem. Sci.* 22:1–2.
- Balsinde, J., M. A. Balboa, P. A. Insel, and E. A. Dennis. 1999. Regulation and inhibition of phospholipase A2. *Annu. Rev. Pharmacol. Toxicol.* 39:175–189.
- Kini, R. M. 1997. *Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism*. John Wiley & Sons, Chichester.
- Six, D. A., and E. A. Dennis. 2000. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. *Biochim. Biophys. Acta.* 1488:1–19.
- Renetseder, R., S. Brunie, B. W. Dijkstra, J. Drenth, and P. B. Sigler. 1985. A comparison of the crystal structures of phospholipase A2 from bovine pancreas and *Crotalus atrox* venom. *J. Biol. Chem.* 260:11627–11634.
- Magro, A. J., A. M. Soares, J. R. Giglio, and M. R. Fontes. 2003. Crystal structures of BnSP-7 and BnSP-6, two Lys49-phospholipases A(2): quaternary structure and inhibition mechanism insights. *Biochem. Biophys. Res. Commun.* 311:713–720.
- Wei, J. F., X. L. Wei, Q. Y. Chen, T. Huang, L. Y. Qiao, W. Y. Wang, Y. L. Xiong, and S. H. He. 2006. N49 phospholipase A2, a unique subgroup of snake venom group II phospholipase A2. *Biochim. Biophys. Acta.* 1760:462–471.
- Wei, J. F., T. Li, X. L. Wei, Q. Y. Sun, F. M. Yang, Q. Y. Chen, W. Y. Wang, Y. L. Xiong, and S. H. He. 2006. Purification, characterization and cytokine release function of a novel Arg-49 phospholipase A(2) from the venom of *Protobothrops mucrosquamatus*. *Biochimie.* 88: 1331–1342.
- Holland, D. R., L. L. Clancy, S. W. Muchmore, T. J. Ryde, H. M. Einspahr, B. C. Finzel, R. L. Heinrikson, and K. D. Watenpaugh. 1990. The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0-Å resolution. *J. Biol. Chem.* 265: 17649–17656.
- Scott, D. L., A. Achari, J. C. Vidal, and P. B. Sigler. 1992. Crystallographic and biochemical studies of the (inactive) Lys-49 phospholipase A2 from the venom of *Agkistrodon piscivorus piscivorus*. *J. Biol. Chem.* 267:22645–22657.
- de Azevedo, W. F., Jr., R. J. Ward, J. M. Gutierrez, and R. K. Arni. 1999. Structure of a Lys49-phospholipase A2 homologue isolated from the venom of *Bothrops nummifer* (jumping viper). *Toxicon.* 37:371–384.
- Lee, W. H., M. T. da Silva Giotto, S. Marangoni, M. H. Toyama, I. Polikarpov, and R. C. Garratt. 2001. Structural basis for low catalytic activity in Lys49 phospholipases A2—a hypothesis: the crystal structure of piratoxin II complexed to fatty acid. *Biochemistry.* 40:28–36.
- Lomonte, B., E. Moreno, A. Tarkowski, L. A. Hanson, and M. Maccarana. 1994. Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from *Bothrops asper* snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. *J. Biol. Chem.* 269:29867–29873.
- Calderon, L., and B. Lomonte. 1998. Immunochemical characterization and role in toxic activities of region 115–129 of myotoxin II, a Lys49 phospholipase A2 from *Bothrops asper* snake venom. *Arch. Biochem. Biophys.* 358:343–350.
- Calderon, L., and B. Lomonte. 1999. Inhibition of the myotoxic activity of *Bothrops asper* myotoxin II in mice by immunization with its synthetic 13-mer peptide 115–129. *Toxicon.* 37:683–687.

18. Lomonte, B., Y. Angulo, and L. Calderon. 2003. An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. *Toxicon*. 42:885–901.
19. Murakami, M. T., and R. K. Arni. 2003. A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A2s. *Toxicon*. 42:903–913.
20. Murakami, M. T., E. Z. Arruda, P. A. Melo, A. B. Martinez, S. Calil-Elias, M. A. Tomaz, B. Lomonte, J. M. Gutierrez, and R. K. Arni. 2005. Inhibition of myotoxic activity of *Bothrops asper* myotoxin II by the anti-trypanosomal drug suramin. *J. Mol. Biol.* 350:416–426.
21. Ambrosio, A. L., M. C. Nonato, H. S. de Araujo, R. Arni, R. J. Ward, C. L. Ownby, D. H. de Souza, and R. C. Garratt. 2005. A molecular mechanism for Lys49-phospholipase A2 activity based on ligand-induced conformational change. *J. Biol. Chem.* 280:7326–7335.
22. Polgar, J., E. M. Magnenat, M. C. Peitsch, T. N. Wells, and K. J. Clemetson. 1996. Asp-49 is not an absolute prerequisite for the enzymic activity of low-M(r) phospholipases A2: purification, characterization and computer modelling of an enzymically active Ser-49 phospholipase A2, ecarpholin S, from the venom of *Echis carinatus* *sochureki* (saw-scaled viper). *Biochem. J.* 319:961–968.
23. Jasti, J., M. Paramasivam, A. Srinivasan, and T. P. Singh. 2004. Structure of an acidic phospholipase A2 from Indian saw-scaled viper (*Echis carinatus*) at 2.6 Å resolution reveals a novel intermolecular interaction. *Acta Crystallogr. D Biol. Crystallogr.* 60:66–72.
24. Ownby, C. L., H. S. Selistre de Araujo, S. P. White, and J. E. Fletcher. 1999. Lysine 49 phospholipase A2 proteins. *Toxicon*. 37:411–445.
25. Joseph, J. S., S. Thirumangalathu, F. Tsang, F. W. Wong, and R. M. Kini. 2003. Trocarin, a blood coagulation factor Xa homologue from snake venom, causes inflammation and mitogenesis. *Toxicon*. 42:769–776.
26. Bordi, F., C. Cametti, S. Sennato, and M. Diociaiuti. 2006. Direct evidence of multicompartiment aggregates in polyelectrolyte-charged liposome complexes. *Biophys. J.* 91:1513–1520.
27. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. In *Methods in Enzymology*. Carter, C.W., and Jr. & R. M. Sweet, editors. Academic Press, New York. 307–326.
28. Vagin, A., and A. Teplyakov. 1997. MOLREP: an automated program for molecular replacement. *J. Appl. Cryst.* 30:1022–1025.
29. Perrakis, A., R. Morris, and V. S. Lamzin. 1999. Automated protein model building combined with iterative structure refinement. *Nat. Struct. Biol.* 6:458–463.
30. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A*. 47:110–119.
31. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography and NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr.* 54:905–921.
32. Laskowski, R. A., M. W. MacArthur, D. S. Moss, and J. M. Thornton. 1993. Procheck: a program to check the stereochemical quality of protein structures. *J. Appl. Cryst.* 26:283–291.
33. Gubensek, F., T. R. Pattabhiraman, and F. E. Russell. 1980. Phospholipase A2 activity of some crotalid snake venoms and fractions. *Toxicon*. 18:699–701.
34. Krizaj, I., A. L. Bieber, A. Ritonja, and F. Gubensek. 1991. The primary structure of ammodytin L, a myotoxic phospholipase A2 homologue from *Vipera ammodytes* venom. *Eur. J. Biochem.* 202:1165–1168.
35. Yoshizumi, K., S. Y. Liu, T. Miyata, S. Saita, M. Ohno, S. Iwanaga, and H. Kihara. 1990. Purification and amino acid sequence of basic protein I, a lysine-49-phospholipase A2 with low activity, from the venom of *Trimeresurus flavoviridis* (habu snake). *Toxicon*. 28:43–54.
36. Liu, S. Y., K. Yoshizumi, N. Oda, M. Ohno, F. Tokunaga, S. Iwanaga, and H. Kihara. 1990. Purification and amino acid sequence of basic protein II, a lysine-49-phospholipase A2 with low activity, from *Trimeresurus flavoviridis* venom. *J. Biochem. (Tokyo)*. 107:400–408.
37. Shimohigashi, Y., A. Tani, H. Matsumoto, K. Nakashima, and Y. Yamaguchi. 1995. Lysine-49-phospholipases A2 from *Trimeresurus flavoviridis* venom are membrane-acting enzymes. *J. Biochem. (Tokyo)*. 118:1037–1044.
38. Rodrigues-Simioni, L., J. Prado-Franceschi, A. C. Cintra, J. R. Giglio, M. S. Jiang, and J. E. Fletcher. 1995. No role for enzymatic activity or dantrolene-sensitive Ca^{2+} stores in the muscular effects of bothropstoxin, a Lys49 phospholipase A2 myotoxin. *Toxicon*. 33:1479–1489.
39. Yamaguchi, Y., Y. Shimohigashi, T. Chiwata, A. Tani, T. Chijiwa, B. Lomonte, and M. Ohno. 1997. Lys-49-phospholipases A2 as active enzyme for beta-arachidonoyl phospholipid bilayer membranes. *Biochem. Mol. Biol. Int.* 43:19–26.
40. Mancin, A. C., A. M. Soares, C. A. Giglio, S. H. Andriao-Escarso, C. A. Vieira, and J. R. Giglio. 1997. The histamine releasers crotamine, protamine and compound 48/80 activate specific proteases and phospholipases A2. *Biochem. Mol. Biol. Int.* 42:1171–1177.
41. Soares, A. M., Y. Oshima-Franco, C. A. Vieira, G. B. Leite, J. E. Fletcher, M. S. Jiang, A. C. Cintra, J. R. Giglio, and L. Rodrigues-Simioni. 2002. Mn^{2+} ions reduce the enzymatic and pharmacological activities of bothropstoxin-I, a myotoxic Lys49 phospholipase A(2) homologue from *Bothrops jararacussu* snake venom. *Int. J. Biochem. Cell Biol.* 34:668–677.
42. Selistre de Araujo, H. S., S. P. White, and C. L. Ownby. 1996. cDNA cloning and sequence analysis of a lysine-49 phospholipase A2 myotoxin from *Agkistrodon contortrix laticinctus* snake venom. *Arch. Biochem. Biophys.* 326:21–30.
43. Ward, R. J., L. Chioato, A. H. de Oliveira, R. Ruller, and J. M. Sa. 2002. Active-site mutagenesis of a Lys49-phospholipase A2: biological and membrane-disrupting activities in the absence of catalysis. *Biochem. J.* 362:89–96.
44. Tsai, I. H., Y. M. Wang, L. C. Au, T. P. Ko, Y. H. Chen, and Y. F. Chu. 2000. Phospholipases A2 from *Callosellasma rhodostoma* venom gland cloning and sequencing of 10 of the cDNAs, three-dimensional modelling and chemical modification of the major isozyme. *Eur. J. Biochem.* 267:6684–6691.
45. Tyler, M. I., D. Barnett, P. Nicholson, I. Spence, and M. E. Howden. 1987. Studies on the subunit structure of textilotoxin, a potent neurotoxin from the venom of the Australian common brown snake (*Pseudonaja textilis*). *Biochim. Biophys. Acta*. 915:210–216.
46. Soares, A. M., S. H. Andriao-Escarso, Y. Angulo, B. Lomonte, J. M. Gutierrez, S. Marangoni, M. H. Toyama, R. K. Arni, and J. R. Giglio. 2000. Structural and functional characterization of myotoxin I, a Lys49 phospholipase A(2) homologue from *Bothrops moojeni* (Caissaca) snake venom. *Arch. Biochem. Biophys.* 373:7–15.
47. Watanabe, L., A. M. Soares, R. J. Ward, M. R. Fontes, and R. K. Arni. 2005. Structural insights for fatty acid binding in a Lys49-phospholipase A2: crystal structure of myotoxin II from *Bothrops moojeni* complexed with stearic acid. *Biochimie*. 87:161–167.
48. Arruda, E. Z., N. M. Silva, R. A. Moraes, and P. A. Melo. 2002. Effect of suramin on myotoxicity of some crotalid snake venoms. *Braz. J. Med. Biol. Res.* 35:723–726.
49. de Oliveira, M., W. L. Cavalcante, E. Z. Arruda, P. A. Melo, M. Dal-Pai Silva, and M. Gallacci. 2003. Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin. *Toxicon*. 42:373–379.
50. Murakami, M. T., M. M. Vicoti, J. R. Abrego, M. R. Lourenzoni, A. C. Cintra, E. Z. Arruda, M. A. Tomaz, P. A. Melo, and R. K. Arni. 2007. Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. *Toxicon*. 49:378–387.
51. Murakami, M., Y. Nakatani, and I. Kudo. 1996. Type II secretory phospholipase A2 associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation. *J. Biol. Chem.* 271:30041–30051.
52. Verheij, H. M., J. J. Volwerk, E. H. Jansen, W. C. Puyk, B. W. Dijkstra, J. Drenth, and G. H. de Haas. 1980. Methylation of histidine-

- 48 in pancreatic phospholipase A2. Role of histidine and calcium ion in the catalytic mechanism. *Biochemistry*. 19:743–750.
53. White, S. P., D. L. Scott, Z. Otwinowski, M. H. Gelb, and P. B. Sigler. 1990. Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. *Science*. 250:1560–1563.
54. Scott, D. L., S. P. White, Z. Otwinowski, W. Yuan, M. H. Gelb, and P. B. Sigler. 1990. Interfacial catalysis: the mechanism of phospholipase A2. *Science*. 250:1541–1546.
55. Nunez, C. E., Y. Angulo, and B. Lomonte. 2001. Identification of the myotoxic site of the Lys49 phospholipase A(2) from *Agkistrodon piscivorus piscivorus* snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. *Toxicon*. 39:1587–1594.
56. Diaz, C., A. Alape, B. Lomonte, T. Olamendi, and J. M. Gutierrez. 1994. Cleavage of the NH2-terminal octapeptide of *Bothrops asper* myotoxic lysine-49 phospholipase A2 reduces its membrane-destabilizing effect. *Arch. Biochem. Biophys.* 312:336–339.
57. Soares, A. M., R. Guerra-Sá, C. R. Borja-Oliveira, V. M. Rodrigues, L. Rodrigues-Simioni, V. Rodrigues, M. R. Fontes, B. Lomonte, J. M. Gutiérrez, and J. R. Giglio. 2000. Structural and functional characterization of BnSP-7, a Lys49 myotoxic phospholipase A(2) homologue from *Bothrops neuwiedi pauloensis* venom. *Arch. Biochem. Biophys.* 378:201–209.
58. Soares, A. M., S. H. Andraio-Escarso, R. K. Bortoleto, L. Rodrigues-Simioni, R. K. Ami, R. J. Ward, J. M. Gutierrez, and J. R. Giglio. 2001. Dissociation of enzymatic and pharmacological properties of piratoxins-I and -III, two myotoxic phospholipases A2 from *Bothrops pirajai* snake venom. *Arch. Biochem. Biophys.* 387:188–196.
59. DeLano, W. S. 2002. The PyMOL Molecular Graphics System. In: <http://www.pymol.org>. Accessed April 7, 2007.